evaluation of the effect for cardio vascular system by administrating EPA thrapy

evaluation of the effect for cardio vascular system by administrating EPA thrapy - EPA trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004024

Enrollment

100

Registered

2010-08-16

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemia

Interventions

Eicosapentaenoic acid

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) hyperlipidemia 2) age: 20-85 years old 3) sex:men, women

Exclusion criteria

Exclusion criteria: 1) with allergy for anti-lipid drug 2) severe chronic renal failure 3) severe liver failure 4) hypo-drug compliance 5) the patients with pregnancy 6) the patients who was judged not to be able to admit drug by doctor

Design outcomes

Primary

Measure	Time frame
1) FMD, ABI, pWV, IMA 2) Cardioechography 3) TG, HDL, LDL, MDA-LDL, lipd acid	—

Secondary

Measure	Time frame
1) liver function 2) Renal function 3) blood test(BNP, FBS, HbA1c, IRI) 5) BMI, waist	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026